Physician profile
Ami Mehra
NPI 1760400634
$63,603.33
in general payments reported to CMS, 2019-2025
23 companies · $1,586 in 2025
The $1,586 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $2,639 · 2021: $3,164 · 2022: $13K · 2023: $8,845 · 2024: $5,436 · 2025: $1,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $4,488 · Travel and Lodging: $820 · Education: $59.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,500.00 |
| Food and Beverage | $4,488.05 |
| Travel and Lodging | $819.63 |
| Education | $59.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $58,613.45 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Amgen INC. | $1,775.91 | 2021-2025 | Tezspire |
| Pfizer INC. | $556.79 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $368.58 | 2023-2025 | Orladeyo |
| Glaxosmithkline, LLC. | $352.04 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $290.49 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $290.28 | 2023-2025 | Cuvitru, Eohilia, Takhzyro |
| Csl Behring | $241.22 | 2020-2025 | Haegarda, Andembry, Hizentra |
| Abbvie INC. | $200.43 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $188.88 | 2025 | |
| Grifols USA, LLC | $136.75 | 2024-2025 | Xembify |
| Pharming Healthcare, INC. | $115.74 | 2022-2025 | Ruconest |
| Genzyme Corporation | $104.11 | 2023-2024 | |
| Lilly USA, LLC | $76.52 | 2025 | Ebglyss |
| Kaleo, INC. | $68.18 | 2024 | Auvi-Q |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $53.17 | 2019 | |
| Ionis Pharmaceuticals, INC. | $44.95 | 2025 | Dawnzera |
| Ars Pharmaceuticals Operations, INC. | $35.35 | 2025 | Neffy |
| Gc Biopharma USA, INC. | $29.96 | 2025 | Alyglo |
| Cycle Pharmaceuticals INC | $20.12 | 2024 | Sajazir |
| Galderma Laboratories, L.P. | $17.07 | 2025 | Nemluvio |
| Alk-Abello, INC | $16.15 | 2019 | |
| Organon LLC | $7.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Mehra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.